Heterozygous and homozygous variants in STX1A cause a neurodevelopmental disorder with or without epilepsy - Luppe, Johannes; Sticht, Heinrich; Lecoquierre, François; Goldenberg, Alice; Gorman, Kathleen; Molloy, Ben; Agolini, Emanuele; Novelli, Antonio; Briuglia, Silvana; Kuismin, Outi; Marcelis, Carlo; Vitobello, Antonio; et al. (medRxiv, 2022)
The neuronal SNARE complex drive synaptic vesicle exocytosis. Therefore, one of its core proteins syntaxin 1A (STX1A) has long been suspected to play a role in neurodevelopmental disorders. We assembled eight individuals harboring rare variants in STX1A who present with a spectrum of intellectual, autism and epilepsy. Causative variants comprise a homozygous splice variant, three de novo missense variants and two inframe deletions of a single amino acid. We observed a phenotype mainly driven by epilepsy in the individuals with missense variants in contrast to intellectual disability and autistic behavior in individuals with single amino acid deletions and the splicing variant. In silico modeling of missense variants and single amino acid deletions show different impaired protein-protein interactions. We hypothesize the two phenotypic courses of affected individuals to be dependent on two different pathogenic mechanisms: (1) a weakened inhibitory STX1A-STXBP1 interaction due to missense variants results in an STX1A-related developmental epileptic encephalopathy and (2) a hampered SNARE complex formation due to inframe deletions causes an STX1A-related intellectual disability and autism phenotype.Competing Interest StatementThe authors have declared no competing interest.Funding StatementF.L. and A.G. received funding from European Union and Region Normandie in the context of Recherche Innovation Normandie (RIN 2018). Europe gets involved in Normandie with the Eu-ropean Regional Development Fund (ERDF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the University of Leipzig, Germany (402/16-ek). All families provided informed consent for clinical phenotyping, genetic testing and publi-cation. If done in a research setting, testing was approved by local ethics committees in the respective institutions.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.DD/IDdevelopmental delay/intellectual disabilityASDautism spectrum disorderOFCoccipitofrontal circumference